Antinuclear Antibodies (ANA), Serum

Mayo Clinic Laboratories' ANA2 catalog entry describes an ELISA-based ANA screen for evaluating patients at risk for ANA-associated systemic autoimmune rheumatic disease (SLE, Sjogren, MCTD), reported in units with weakly positive/positive/strongly positive cutoffs and ordering guidance pointing to the Connective Tissue Disease Cascade for follow-up. Candidate notes: Method: ELISA (not IFA) — reports a semiquantitative unit value rather than titer/pattern Reference values: Negative <=1.0 U; weakly positive 1.1-2.9 U; positive 3.0-5.9 U; strongly positive >=6.0 U (all ages) Ordering guidance: if connective tissue disorder is suspected, use CTDC (Connective Tissue Disease Cascade) instead; for autoimmune liver disease, use ALDG2 Limits noted in the record: ELISA method does not report IFA titer or staining pattern, limiting follow-up guidance by pattern Units are assay-specific and not comparable across laboratories A positive ANA is not a diagnosis. Claims in this record are not verified.

A positive ANA is not a diagnosis. Claims in this record are not verified.

source